1 / 29

Standard 7 – Blood and blood products

Standard 7 – Blood and blood products. Philippa Kirkpatrick April 2013. Why a blood standard?. There are inherent risks associated with transfusion practice Transfusion has been associated with increased morbidity and mortality Transfusion is ingrained in the culture of medical practice

yvonne
Download Presentation

Standard 7 – Blood and blood products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Standard 7 – Blood and blood products Philippa Kirkpatrick April 2013

  2. Why a blood standard? • There are inherent risks associated with transfusion practice • Transfusion has been associated with increased morbidity and mortality • Transfusion is ingrained in the culture of medical practice • Reports suggest a significant proportion of transfusions are inappropriate • There are high wastage rates at some health service organisations • There is significant room for improvement in practice to improve quality and safety

  3. Scope - activities • The Blood Standard covers: • Use of blood and blood products– the prescribing practice and clinical use of blood and blood products, and whether or not those products are prescribed and used appropriately • Management of blood and blood products - handling, transport, storage (including inventory management) of blood and blood products • Administration of blood and blood products - the process used to deliver the product to the patient.

  4. Scope Currently covered by Standard 7 • Fresh blood products eg • Red cells • Platelets • Plasma • Cryoprecipitate • Serum eye drops • Plasma derived products eg • IVIg • RhD immunoglobulin • Clotting factors Recombinant clotting factors Classes of products funded under National Blood Arrangements Not currently covered by Standard 7 Haematopoietic progenitor cells • Monoclonal antibodies • Vaccines • Other recombinant products • Plasma derived products eg • Tisseel • Artiss • C1-INH • Fibrinogen Classes of products not funded under National Blood Arrangements Blood Biological Medicine

  5. Three main areas of concern • Decision-making regarding the clinical use of blood components • Patient identification and labelling of pre-transfusion specimens • Bedside verification that the correct blood is given to the intended recipient *Source: Haemovigilance Report 2010

  6. Criterion OneGovernance and systems

  7. Transfusion quality improvement system (Action 7.4.1) Improve quality and use of policies (7.1.3) Improve documentation of transfusion (7.5.3) Reduce wastage (7.8.2) Reduce adverse event risks (7.3.1) Improve documentation of consent (7.11.1) Reduce management risks (7.7.2) Reduce systems risks (7.2.2) Reduce administration risks (7.6.2) Improve provision of information to patients (7.10.1)

  8. Policies, procedures and protocols (Action 7.1.1) • You should have policies, procedures and protocols that reflect best practice, and national evidence based guidelines where they are available. • Your policies, procedures and protocols should cover the spectrum of: • Use of blood and blood products • Management of blood and blood products • Administration of blood and blood products

  9. Quality improvement cycle Identify what you will do - develop or identify policies, procedures or protocols Take action to improve uptake and improve their quality Implement the policies Monitor their use AND monitor their quality

  10. Transfusion governance group (Action 7.4.1) What about small organisations? • Oversight of the program • Review reports • Identify recurring issues • Root cause analysis of incidents • Develop or agree action plan • Evaluate effectiveness of actions Consider alignment and linkages with Standard One

  11. Criterion TwoDocumenting patient information

  12. The patient clinical record (Action 7.5.1) • A best possible history of blood product usage and relevant clinical and product information is documented in the patient clinical record • This action builds on Action 1.9.1 by identifying the information relevant to transfusion of blood and blood products that should be documented

  13. Patient documentation case study What actions are required to demonstrate compliance with the Standard?

  14. Case Study Hospital One • Transfusion governance group has reviewed findings and developed and implemented an action plan, for example: • Reviewed policy • Implemented training of all staff • Identified staff associated with non-compliance and communicated directly with them • Made changes to the IT system to facilitate inclusion of all information (prompts) • Increased frequency of audit on the hospital audit plan • Initiated more regular spot checks of fate of product against patient records Outcome: the action plan is matched with the level of compliance. This would be likely be assessed as meeting the requirement, but the health service organisation should also demonstrate improvement in next cycle.

  15. Case StudyHospital One • Audit report does not have a management response or action plan • They posted on the intranet a reminder to document transfusion in the patient clinical record • They have not undertaken any other follow up and the next audit is scheduled for one year away Outcome: the action plan is not matched with the level of compliance. The health service organisation needs to demonstrate additional work prior to accreditation.

  16. Case StudyHospital Two • They posted on the intranet a reminder to document transfusion in the patient clinical record • They have not undertaken any other follow up and the next audit is scheduled for one year away Outcome: the action plan is matched with the level of compliance. This would be likely to be assessed as meeting the requirement.

  17. Managing adverse events • Recognise and respond to adverse events • Document adverse events in the patient clinical record • Take action to reduce the risk of adverse events as part of your transfusion quality improvement system

  18. Complexities of incident monitoring and reporting 7.6.1 – Document in patient clinical record Patient record 7.6.3.- Report to pathology service provider, Blood Service or product manufacturer whenever appropriate External report 7.3.1. - Report in local incident system and review by Transfusion Governance Group Local report 7.3.2. - Review by highest governance level of incident summary and analysis Exec review 7.3.3. – Participate in state haemovigilance reporting In some cases will be extracted from local system or, may require reporting to the state system State report 7.3.3 – Participate in national haemovigilance reporting In some cases will be extracted from state system or, may require reporting to the national system National report

  19. Criterion ThreeManaging blood and blood product safety

  20. Management of blood and blood products • Blood must be stored and handled appropriately to prevent risk to patients. Systems should be implemented to reduce risks associated with receipt, storage, collection, and transport (Action 7.7.1 and 7.7.2) • Wastage of blood should beminimised (Action 7.8.1 and 7.8.2)

  21. Responsibility where services are outsourced • Many health service organisations receive blood from an outsourced pathology • It remains the health service organisation’s responsibility to demonstrate compliance with the Standard

  22. Criterion FourCommunicating with patients and carers

  23. Communication (Actions 7.9.1, 7.9.2 and 7.10.1) • Develop or identify resources to inform patients and their carers about the alternatives, risk and benefits of transfusion (Action 7.9.1) • Provide this information to patients and their carers in a format that is understood and meaningful (7.10.1) • Allow patients and carers to partner in decisions on their care based on the communication on the alternatives, risks and benefits of transfusion (Action 7.9.2)

  24. Consent (Action 7.11.1) • Have a documented consent policy which is specific to, or includes transfusion of blood and blood products • Ensure written and documented consent meets local policy • Ensure the consent is actually informed – link with 7.9 and 7.10 • Assess compliance with the consent policy is assessed, and take actions to increase compliance

  25. Resources

  26. Available resources Clinical practice guidelines National Blood Authority www.blood.gov.au/guidelines • Patient Blood Management Guidelines Module 1: Critical Bleeding Massive Transfusion Module 2: Perioperative Module 3: Medical Module 4: Critical Care Module 5: Obstetric Module 6: Paediatric/Neonates • Guidelines on the Prophylactic Use of Rh D Immunoglobulin (anti-D) in Obstetrics • Criteria for the Clinical Use of Intravenous Immunoglobulin (second edition) NHMRC guidelines portal www.nhmrc.gov.au/guidelines • Factor VIII and FIX Guidelines • Warfarin Reversal Consensus Guidelines Australian and New Zealand Society of Blood Transfusion (ANZSBT) guidelines and publications www.anzsbt.org.au/publications/

  27. Available resources Product information and product management • 10 Tips to Help Manage you Blood Product Inventory http://www.nba.gov.au/supply/10-tips.pdf • Managing blood and blood product inventory – Guidelines for Australian Health Providers http://www.nba.gov.au/supply/inventory-guidelines.pdf • Australian Red Cross Blood Service Blood Component Information Circular http://www.transfusion.com.au/sites/default/files/BCI%202012.pdf • The Australian Red Cross Blood Service blood components and products web site http://www.transfusion.com.au/blood_products • BloodSafe eLearning Australia module on Transporting Blood https://www.bloodsafelearning.org.au/ • ANZSBT Guidelines for the Administration of Blood Products http://www.anzsbt.org.au/publications/ • ANZSBT Guidelines for Pre-Transfusion Laboratory Practice http://www.anzsbt.org.au/publications/ • National Pathology Accreditation Advisory Council (NPAAC) Requirements for Transfusion Laboratory Practice http://www.anzsbt.org.au/news/documents/07NPAACReqforTLP.pdf • Australian Standard for Medical Refrigeration Equipment – For the Storage of Blood and Blood Products (AS3864) http://infostore.saiglobal.com/store/Details.aspx?ProductID=1600490 • NBA BloodNet http://www.blood.gov.au/bloodnet/ • NBA BloodPortal https://portal.blood.gov.au/ • Flippin’ Blood http://www.transfusion.com.au/sites/default/files/Flippin%20Blood%20ONLINE.pdf

  28. Available resources Adverse event recognition and reporting • See Jurisdictional programs • NBA Haemovigilance Reports 2008 http://www.blood.gov.au/haemovigilance/ • National Haemovigilance Data Dictionary http://www.blood.gov.au/haemovigilance/ • Flippin’ Blood http://www.transfusion.com.au/sites/default/files/Flippin%20Blood%20ONLINE.pdf • ANZSBT Guidelines for the Administration of Blood Products(http://www.anzsbt.org.au/publications/) Patient information and consent • See Jurisdictional programs • The Australian Red Cross Blood Service – Information for Patients www.mytransfusion.com.au Jurisdictional Programs • New South Wales – Blood Watch http://www.cec.health.nsw.gov.au/programs/blood-watch • Queensland iBlood Management Program http://www.health.qld.gov.au/qhcss/qbmp/ • South Australia – BloodSafe http://www.health.sa.gov.au/bloodsafe/ • Victoria – Blood Matters http://www.health.vic.gov.au/bloodmatters/ • Western Australia Patient Blood Management Program http://www.health.wa.gov.au/bloodmanagement

More Related